243 related articles for article (PubMed ID: 24973720)
1. In vivo proof of concept of oral insulin delivery based on a co-administration strategy with the cell-penetrating peptide penetratin.
Nielsen EJ; Yoshida S; Kamei N; Iwamae R; Khafagy el-S; Olsen J; Rahbek UL; Pedersen BL; Takayama K; Takeda-Morishita M
J Control Release; 2014 Sep; 189():19-24. PubMed ID: 24973720
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the Key Factors for Optimizing the in Vivo Oral Delivery of Insulin by Using a Noncovalent Strategy with Cell-Penetrating Peptides.
Kamei N; Shigei C; Hasegawa R; Takeda-Morishita M
Biol Pharm Bull; 2018; 41(2):239-246. PubMed ID: 29386483
[TBL] [Abstract][Full Text] [Related]
3. Dependence of Intestinal Absorption Profile of Insulin on Carrier Morphology Composed of β-Cyclodextrin-Grafted Chitosan.
Daimon Y; Kamei N; Kawakami K; Takeda-Morishita M; Izawa H; Takechi-Haraya Y; Saito H; Sakai H; Abe M; Ariga K
Mol Pharm; 2016 Dec; 13(12):4034-4042. PubMed ID: 27749081
[TBL] [Abstract][Full Text] [Related]
4. Effect of different intestinal conditions on the intermolecular interaction between insulin and cell-penetrating peptide penetratin and on its contribution to stimulation of permeation through intestinal epithelium.
Kamei N; Aoyama Y; Khafagy el-S; Henmi M; Takeda-Morishita M
Eur J Pharm Biopharm; 2015 Aug; 94():42-51. PubMed ID: 25960330
[TBL] [Abstract][Full Text] [Related]
5. Region-Dependent Role of Cell-Penetrating Peptides in Insulin Absorption Across the Rat Small Intestinal Membrane.
Khafagy el-S; Iwamae R; Kamei N; Takeda-Morishita M
AAPS J; 2015 Nov; 17(6):1427-37. PubMed ID: 26216471
[TBL] [Abstract][Full Text] [Related]
6. Impact Of Penetratin Stereochemistry On The Oral Bioavailability Of Insulin-Loaded Solid Lipid Nanoparticles.
Alsulays BB; Anwer MK; Soliman GA; Alshehri SM; Khafagy ES
Int J Nanomedicine; 2019; 14():9127-9138. PubMed ID: 31819423
[TBL] [Abstract][Full Text] [Related]
7. One-month subchronic toxicity study of cell-penetrating peptides for insulin nasal delivery in rats.
Khafagy el-S; Kamei N; Nielsen EJ; Nishio R; Takeda-Morishita M
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):736-43. PubMed ID: 24060698
[TBL] [Abstract][Full Text] [Related]
8. Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates.
Sheng J; He H; Han L; Qin J; Chen S; Ru G; Li R; Yang P; Wang J; Yang VC
J Control Release; 2016 Jul; 233():181-90. PubMed ID: 27178809
[TBL] [Abstract][Full Text] [Related]
9. Penetratin derivative-based nanocomplexes for enhanced intestinal insulin delivery.
Zhu X; Shan W; Zhang P; Jin Y; Guan S; Fan T; Yang Y; Zhou Z; Huang Y
Mol Pharm; 2014 Jan; 11(1):317-28. PubMed ID: 24255985
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption.
Kamei N; Morishita M; Eda Y; Ida N; Nishio R; Takayama K
J Control Release; 2008 Nov; 132(1):21-5. PubMed ID: 18727945
[TBL] [Abstract][Full Text] [Related]
11. Effect of cell-penetrating peptides on the nasal absorption of insulin.
Khafagy el-S; Morishita M; Isowa K; Imai J; Takayama K
J Control Release; 2009 Jan; 133(2):103-8. PubMed ID: 18930084
[TBL] [Abstract][Full Text] [Related]
12. Noninvasive insulin delivery: the great potential of cell-penetrating peptides.
Kamei N; Nielsen EJ; Khafagy el-S; Takeda-Morishita M
Ther Deliv; 2013 Mar; 4(3):315-26. PubMed ID: 23442079
[TBL] [Abstract][Full Text] [Related]
13. Combination Strategy with Complexation Hydrogels and Cell-Penetrating Peptides for Oral Delivery of Insulin.
Fukuoka Y; Khafagy ES; Goto T; Kamei N; Takayama K; Peppas NA; Takeda-Morishita M
Biol Pharm Bull; 2018; 41(5):811-814. PubMed ID: 29709919
[TBL] [Abstract][Full Text] [Related]
14. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides.
Kamei N; Takeda-Morishita M
J Control Release; 2015 Jan; 197():105-10. PubMed ID: 25445695
[TBL] [Abstract][Full Text] [Related]
15. Use of a non-covalent cell-penetrating peptide strategy to enhance the nasal delivery of interferon beta and its PEGylated form.
Iwase Y; Kamei N; Khafagy el-S; Miyamoto M; Takeda-Morishita M
Int J Pharm; 2016 Aug; 510(1):304-10. PubMed ID: 27343364
[TBL] [Abstract][Full Text] [Related]
16. Enhanced oral absorption of insulin using colon-specific nanoparticles co-modified with amphiphilic chitosan derivatives and cell-penetrating peptides.
Guo F; Ouyang T; Peng T; Zhang X; Xie B; Yang X; Liang D; Zhong H
Biomater Sci; 2019 Mar; 7(4):1493-1506. PubMed ID: 30672923
[TBL] [Abstract][Full Text] [Related]
17. Visualization and Quantitative Assessment of the Brain Distribution of Insulin through Nose-to-Brain Delivery Based on the Cell-Penetrating Peptide Noncovalent Strategy.
Kamei N; Shingaki T; Kanayama Y; Tanaka M; Zochi R; Hasegawa K; Watanabe Y; Takeda-Morishita M
Mol Pharm; 2016 Mar; 13(3):1004-11. PubMed ID: 26795701
[TBL] [Abstract][Full Text] [Related]
18. Oral biodrug delivery using cell-penetrating peptide.
Khafagy el-S; Morishita M
Adv Drug Deliv Rev; 2012 May; 64(6):531-9. PubMed ID: 22245080
[TBL] [Abstract][Full Text] [Related]
19. Enhanced oral bioavailability of insulin using PLGA nanoparticles co-modified with cell-penetrating peptides and Engrailed secretion peptide (Sec).
Zhu S; Chen S; Gao Y; Guo F; Li F; Xie B; Zhou J; Zhong H
Drug Deliv; 2016 Jul; 23(6):1980-91. PubMed ID: 26181841
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging analysis of intestinal insulin absorption boosted by cell-penetrating peptides by using positron emission tomography.
Kamei N; Morishita M; Kanayama Y; Hasegawa K; Nishimura M; Hayashinaka E; Wada Y; Watanabe Y; Takayama K
J Control Release; 2010 Aug; 146(1):16-22. PubMed ID: 20457194
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
